Evaluation of Tolerability and Immunogenicity of GARDASIL in Healthy Females, Between 16 and 26 Years of Age, in India.

Trial Profile

Evaluation of Tolerability and Immunogenicity of GARDASIL in Healthy Females, Between 16 and 26 Years of Age, in India.

Suspended
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Pharmacodynamics; Registrational
  • Most Recent Events

    • 13 Jan 2011 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 30 Sep 2010 Planned end date changed from 1 Apr 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
    • 03 Feb 2010 New source identified and integrated (Clinical Trials Registry - India).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top